Compile Data Set for Download or QSAR

Found 813 hits Enz. Inhib. hit(s) with Target = 'Proto-oncogene tyrosine-protein kinase receptor Ret [V804L]'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311699 (Ex. Cpd. 151 | US10807986, Example 151 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCSCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H30N6O2S/c1-26(9-10-26)32-20(4-3-11-31-12-14-35-15-13-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-7-5-18(6-8-19)16-34-2/h5-8,17H,9-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311643 (Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C22H23N5O2/c1-4-5-16-17(21(28)26-15-8-6-14(7-9-15)12-29-3)18-19(23)24-13-25-20(18)27(16)22(2)10-11-22/h6-9,13H,10-12H2,1-3H3,(H,26,28)(H2,23,24,25)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311622 (Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2c(Br)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H20BrN5OS/c1-19(7-8-19)25-15(20)13(14-16(21)22-10-23-17(14)25)18(26)24-12-5-3-11(4-6-12)9-27-2/h3-6,10H,7-9H2,1-2H3,(H,24,26)(H2,21,22,23)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311651 (Ex. Cpd. 103 | US10807986, Example 103 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3(O)CCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H29N5O3/c1-25(13-14-25)31-19(5-3-10-26(33)11-4-12-26)20(21-22(27)28-16-29-23(21)31)24(32)30-18-8-6-17(7-9-18)15-34-2/h6-9,16,33H,4,10-15H2,1-2H3,(H,30,32)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311699 (Ex. Cpd. 151 | US10807986, Example 151 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCSCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H30N6O2S/c1-26(9-10-26)32-20(4-3-11-31-12-14-35-15-13-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-7-5-18(6-8-19)16-34-2/h5-8,17H,9-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				Citation and Details BindingDB Entry DOI: 10.7270/Q2280BR0
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311639 (Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cnc4cccnn34)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H24N8O2/c1-27(11-12-27)34-20(10-9-19-14-29-21-4-3-13-32-35(19)21)22(23-24(28)30-16-31-25(23)34)26(36)33-18-7-5-17(6-8-18)15-37-2/h3-8,13-14,16H,11-12,15H2,1-2H3,(H,33,36)(H2,28,30,31)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311634 (Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC(C)(C)O)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H29N5O3/c1-24(2,32)11-5-6-18-19(23(31)29-17-9-7-16(8-10-17)14-33-4)20-21(26)27-15-28-22(20)30(18)25(3)12-13-25/h7-10,15,32H,11-14H2,1-4H3,(H,29,31)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311622 (Ex. Cpd. 59 | US10807986, Example 59 | US11046696,...) Show SMILES CSCc1ccc(NC(=O)c2c(Br)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C19H20BrN5OS/c1-19(7-8-19)25-15(20)13(14-16(21)22-10-23-17(14)25)18(26)24-12-5-3-11(4-6-12)9-27-2/h3-6,10H,7-9H2,1-2H3,(H,24,26)(H2,21,22,23)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311639 (Ex. Cpd. 91 | US10807986, Example 91 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cnc4cccnn34)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H24N8O2/c1-27(11-12-27)34-20(10-9-19-14-29-21-4-3-13-32-35(19)21)22(23-24(28)30-16-31-25(23)34)26(36)33-18-7-5-17(6-8-18)15-37-2/h3-8,13-14,16H,11-12,15H2,1-2H3,(H,33,36)(H2,28,30,31)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311705 (Ex. Cpd. 157 | US10807986, Example 157 | US1104669...) Show SMILES CCC(O)CC#Cc1c(C(=O)Nc2ccc(COC)cc2)c2c(N)ncnc2n1C1(C)CC1 Show InChI InChI=1S/C25H29N5O3/c1-4-18(31)6-5-7-19-20(24(32)29-17-10-8-16(9-11-17)14-33-3)21-22(26)27-15-28-23(21)30(19)25(2)12-13-25/h8-11,15,18,31H,4,6,12-14H2,1-3H3,(H,29,32)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311717 (Ex. Cpd. 169 | US10807986, Example 169 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCn3cccc3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H26N6O2/c1-26(11-12-26)32-20(6-5-15-31-13-3-4-14-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-9-7-18(8-10-19)16-34-2/h3-4,7-10,13-14,17H,11-12,15-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311705 (Ex. Cpd. 157 | US10807986, Example 157 | US1104669...) Show SMILES CCC(O)CC#Cc1c(C(=O)Nc2ccc(COC)cc2)c2c(N)ncnc2n1C1(C)CC1 Show InChI InChI=1S/C25H29N5O3/c1-4-18(31)6-5-7-19-20(24(32)29-17-10-8-16(9-11-17)14-33-3)21-22(26)27-15-28-23(21)30(19)25(2)12-13-25/h8-11,15,18,31H,4,6,12-14H2,1-3H3,(H,29,32)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311643 (Ex. Cpd. 95 | US10807986, Example 95 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C22H23N5O2/c1-4-5-16-17(21(28)26-15-8-6-14(7-9-15)12-29-3)18-19(23)24-13-25-20(18)27(16)22(2)10-11-22/h6-9,13H,10-12H2,1-3H3,(H,26,28)(H2,23,24,25)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311651 (Ex. Cpd. 103 | US10807986, Example 103 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3(O)CCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H29N5O3/c1-25(13-14-25)31-19(5-3-10-26(33)11-4-12-26)20(21-22(27)28-16-29-23(21)31)24(32)30-18-8-6-17(7-9-18)15-34-2/h6-9,16,33H,4,10-15H2,1-2H3,(H,30,32)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311699 (Ex. Cpd. 151 | US10807986, Example 151 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCSCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H30N6O2S/c1-26(9-10-26)32-20(4-3-11-31-12-14-35-15-13-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-7-5-18(6-8-19)16-34-2/h5-8,17H,9-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311700 (Ex. Cpd. 152 | US10807986, Example 152 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H31N5O3/c1-27(12-13-27)32-21(5-3-4-18-10-14-35-15-11-18)22(23-24(28)29-17-30-25(23)32)26(33)31-20-8-6-19(7-9-20)16-34-2/h6-9,17-18H,4,10-16H2,1-2H3,(H,31,33)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311717 (Ex. Cpd. 169 | US10807986, Example 169 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCn3cccc3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H26N6O2/c1-26(11-12-26)32-20(6-5-15-31-13-3-4-14-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-9-7-18(8-10-19)16-34-2/h3-4,7-10,13-14,17H,11-12,15-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311700 (Ex. Cpd. 152 | US10807986, Example 152 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H31N5O3/c1-27(12-13-27)32-21(5-3-4-18-10-14-35-15-11-18)22(23-24(28)29-17-30-25(23)32)26(33)31-20-8-6-19(7-9-20)16-34-2/h6-9,17-18H,4,10-16H2,1-2H3,(H,31,33)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311634 (Ex. Cpd. 86 | US10807986, Example 86 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC(C)(C)O)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H29N5O3/c1-24(2,32)11-5-6-18-19(23(31)29-17-9-7-16(8-10-17)14-33-4)20-21(26)27-15-28-22(20)30(18)25(3)12-13-25/h7-10,15,32H,11-14H2,1-4H3,(H,29,31)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.300	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311723 (Ex. Cpd. 175 | US10807986, Example 175 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cncc(F)c3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H23FN6O2/c1-26(9-10-26)33-20(8-5-17-11-18(27)13-29-12-17)21(22-23(28)30-15-31-24(22)33)25(34)32-19-6-3-16(4-7-19)14-35-2/h3-4,6-7,11-13,15H,9-10,14H2,1-2H3,(H,32,34)(H2,28,30,31)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311652 (Ex. Cpd. 104 | US10807986, Example 104 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC(O)C3CC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H27N5O3/c1-25(11-12-25)30-18(9-10-19(31)16-5-6-16)20(21-22(26)27-14-28-23(21)30)24(32)29-17-7-3-15(4-8-17)13-33-2/h3-4,7-8,14,16,19,31H,5-6,11-13H2,1-2H3,(H,29,32)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311636 (Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H30N6O2/c1-26(11-12-26)32-20(6-5-15-31-13-3-4-14-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-9-7-18(8-10-19)16-34-2/h7-10,17H,3-4,11-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311652 (Ex. Cpd. 104 | US10807986, Example 104 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC(O)C3CC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H27N5O3/c1-25(11-12-25)30-18(9-10-19(31)16-5-6-16)20(21-22(26)27-14-28-23(21)30)24(32)29-17-7-3-15(4-8-17)13-33-2/h3-4,7-8,14,16,19,31H,5-6,11-13H2,1-2H3,(H,29,32)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311653 (Ex. Cpd. 105 | US10807986, Example 105 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCCCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H32N6O2/c1-27(12-13-27)33-21(7-6-16-32-14-4-3-5-15-32)22(23-24(28)29-18-30-25(23)33)26(34)31-20-10-8-19(9-11-20)17-35-2/h8-11,18H,3-5,12-17H2,1-2H3,(H,31,34)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311653 (Ex. Cpd. 105 | US10807986, Example 105 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCCCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H32N6O2/c1-27(12-13-27)33-21(7-6-16-32-14-4-3-5-15-32)22(23-24(28)29-18-30-25(23)33)26(34)31-20-10-8-19(9-11-20)17-35-2/h8-11,18H,3-5,12-17H2,1-2H3,(H,31,34)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311723 (Ex. Cpd. 175 | US10807986, Example 175 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cncc(F)c3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H23FN6O2/c1-26(9-10-26)33-20(8-5-17-11-18(27)13-29-12-17)21(22-23(28)30-15-31-24(22)33)25(34)32-19-6-3-16(4-7-19)14-35-2/h3-4,6-7,11-13,15H,9-10,14H2,1-2H3,(H,32,34)(H2,28,30,31)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311636 (Ex. Cpd. 88 | US10807986, Example 88 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H30N6O2/c1-26(11-12-26)32-20(6-5-15-31-13-3-4-14-31)21(22-23(27)28-17-29-24(22)32)25(33)30-19-9-7-18(8-10-19)16-34-2/h7-10,17H,3-4,11-16H2,1-2H3,(H,30,33)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.400	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311704 (Ex. Cpd. 156 | US10807986, Example 156 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3NC(=O)NC3=O)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H25N7O4/c1-25(10-11-25)32-17(5-3-4-16-22(33)31-24(35)30-16)18(19-20(26)27-13-28-21(19)32)23(34)29-15-8-6-14(7-9-15)12-36-2/h6-9,13,16H,4,10-12H2,1-2H3,(H,29,34)(H2,26,27,28)(H2,30,31,33,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311679 (Ex. Cpd. 131 | US10807986, Example 131 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC3(O)CCCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H29N5O3/c1-25(13-14-25)31-19(9-12-26(33)10-3-4-11-26)20(21-22(27)28-16-29-23(21)31)24(32)30-18-7-5-17(6-8-18)15-34-2/h5-8,16,33H,3-4,10-11,13-15H2,1-2H3,(H,30,32)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311660 (Ex. Cpd. 112 | US10807986, Example 112) Show SMILES COCc1ccc(NC(=O)c2c(C#CC3CCC(=O)CC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H29N5O3/c1-27(13-14-27)32-21(12-7-17-5-10-20(33)11-6-17)22(23-24(28)29-16-30-25(23)32)26(34)31-19-8-3-18(4-9-19)15-35-2/h3-4,8-9,16-17H,5-6,10-11,13-15H2,1-2H3,(H,31,34)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311703 (Ex. Cpd. 155 | US10807986, Example 155 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3ccc(N)nc3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H25N7O2/c1-26(11-12-26)33-19(9-5-16-6-10-20(27)29-13-16)21(22-23(28)30-15-31-24(22)33)25(34)32-18-7-3-17(4-8-18)14-35-2/h3-4,6-8,10,13,15H,11-12,14H2,1-2H3,(H2,27,29)(H,32,34)(H2,28,30,31)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311707 (Ex. Cpd. 159 | US10807986, Example 159 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cnc4ccoc4c3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C28H24N6O3/c1-28(10-11-28)34-21(8-5-18-13-22-20(30-14-18)9-12-37-22)23(24-25(29)31-16-32-26(24)34)27(35)33-19-6-3-17(4-7-19)15-36-2/h3-4,6-7,9,12-14,16H,10-11,15H2,1-2H3,(H,33,35)(H2,29,31,32)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311707 (Ex. Cpd. 159 | US10807986, Example 159 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cnc4ccoc4c3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C28H24N6O3/c1-28(10-11-28)34-21(8-5-18-13-22-20(30-14-18)9-12-37-22)23(24-25(29)31-16-32-26(24)34)27(35)33-19-6-3-17(4-7-19)15-36-2/h3-4,6-7,9,12-14,16H,10-11,15H2,1-2H3,(H,33,35)(H2,29,31,32)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311704 (Ex. Cpd. 156 | US10807986, Example 156 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3NC(=O)NC3=O)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H25N7O4/c1-25(10-11-25)32-17(5-3-4-16-22(33)31-24(35)30-16)18(19-20(26)27-13-28-21(19)32)23(34)29-15-8-6-14(7-9-15)12-36-2/h6-9,13,16H,4,10-12H2,1-2H3,(H,29,34)(H2,26,27,28)(H2,30,31,33,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311703 (Ex. Cpd. 155 | US10807986, Example 155 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3ccc(N)nc3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H25N7O2/c1-26(11-12-26)33-19(9-5-16-6-10-20(27)29-13-16)21(22-23(28)30-15-31-24(22)33)25(34)32-18-7-3-17(4-8-18)14-35-2/h3-4,6-8,10,13,15H,11-12,14H2,1-2H3,(H2,27,29)(H,32,34)(H2,28,30,31)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311679 (Ex. Cpd. 131 | US10807986, Example 131 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC3(O)CCCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H29N5O3/c1-25(13-14-25)31-19(9-12-26(33)10-3-4-11-26)20(21-22(27)28-16-29-23(21)31)24(32)30-18-7-5-17(6-8-18)15-34-2/h5-8,16,33H,3-4,10-11,13-15H2,1-2H3,(H,30,32)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311660 (Ex. Cpd. 112 | US10807986, Example 112) Show SMILES COCc1ccc(NC(=O)c2c(C#CC3CCC(=O)CC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H29N5O3/c1-27(13-14-27)32-21(12-7-17-5-10-20(33)11-6-17)22(23-24(28)29-16-30-25(23)32)26(34)31-19-8-3-18(4-9-19)15-35-2/h3-4,8-9,16-17H,5-6,10-11,13-15H2,1-2H3,(H,31,34)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.5	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311673 (Ex. Cpd. 125 | US10807986, Example 125 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3(O)COC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H27N5O4/c1-24(10-11-24)30-18(4-3-9-25(32)13-34-14-25)19(20-21(26)27-15-28-22(20)30)23(31)29-17-7-5-16(6-8-17)12-33-2/h5-8,15,32H,9-14H2,1-2H3,(H,29,31)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311741 (Ex. Cpd. 193 | US10807986, Example 193 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cncs3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C24H22N6O2S/c1-24(9-10-24)30-18(8-7-17-11-26-14-33-17)19(20-21(25)27-13-28-22(20)30)23(31)29-16-5-3-15(4-6-16)12-32-2/h3-6,11,13-14H,9-10,12H2,1-2H3,(H,29,31)(H2,25,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311637 (Ex. Cpd. 89) Show SMILES COCc1ccc(NC(=O)c2c(OCC3CCCO3)n(c3ncncc23)C2(C)CC2)cc1 Show InChI InChI=1S/C24H28N4O4/c1-24(9-10-24)28-21-19(12-25-15-26-21)20(23(28)32-14-18-4-3-11-31-18)22(29)27-17-7-5-16(6-8-17)13-30-2/h5-8,12,15,18H,3-4,9-11,13-14H2,1-2H3,(H,27,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311635 (Ex. Cpd. 87 | US10807986, Example 87 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H29N5O3/c1-26(11-12-26)31-20(8-5-17-9-13-34-14-10-17)21(22-23(27)28-16-29-24(22)31)25(32)30-19-6-3-18(4-7-19)15-33-2/h3-4,6-7,16-17H,9-15H2,1-2H3,(H,30,32)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM469423 (US10807986, Example 89 | US11046696, Compound 89) Show SMILES COCc1ccc(NC(=O)c2c(OC[C@H]3CCCO3)n(c3ncnc(N)c23)C2(C)CC2)cc1 |r| Show InChI InChI=1S/C24H29N5O4/c1-24(9-10-24)29-21-18(20(25)26-14-27-21)19(23(29)33-13-17-4-3-11-32-17)22(30)28-16-7-5-15(6-8-16)12-31-2/h5-8,14,17H,3-4,9-13H2,1-2H3,(H,28,30)(H2,25,26,27)/t17-/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311708 (Ex. Cpd. 160 | US10807986, Example 160 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cn[nH]c3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C24H23N7O2/c1-24(9-10-24)31-18(8-5-16-11-28-29-12-16)19(20-21(25)26-14-27-22(20)31)23(32)30-17-6-3-15(4-7-17)13-33-2/h3-4,6-7,11-12,14H,9-10,13H2,1-2H3,(H,28,29)(H,30,32)(H2,25,26,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311691 (Ex. Cpd. 143 | US10807986, Example 143 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3(O)CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H31N5O4/c1-26(10-11-26)32-20(4-3-9-27(34)12-14-36-15-13-27)21(22-23(28)29-17-30-24(22)32)25(33)31-19-7-5-18(6-8-19)16-35-2/h5-8,17,34H,9-16H2,1-2H3,(H,31,33)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311741 (Ex. Cpd. 193 | US10807986, Example 193 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cncs3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C24H22N6O2S/c1-24(9-10-24)30-18(8-7-17-11-26-14-33-17)19(20-21(25)27-13-28-22(20)30)23(31)29-16-5-3-15(4-6-16)12-32-2/h3-6,11,13-14H,9-10,12H2,1-2H3,(H,29,31)(H2,25,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311708 (Ex. Cpd. 160 | US10807986, Example 160 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#Cc3cn[nH]c3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C24H23N7O2/c1-24(9-10-24)31-18(8-5-16-11-28-29-12-16)19(20-21(25)26-14-27-22(20)31)23(32)30-17-6-3-15(4-7-17)13-33-2/h3-4,6-7,11-12,14H,9-10,13H2,1-2H3,(H,28,29)(H,30,32)(H2,25,26,27)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311700 (Ex. Cpd. 152 | US10807986, Example 152 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H31N5O3/c1-27(12-13-27)32-21(5-3-4-18-10-14-35-15-11-18)22(23-24(28)29-17-30-25(23)32)26(33)31-20-8-6-19(7-9-20)16-34-2/h6-9,17-18H,4,10-16H2,1-2H3,(H,31,33)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
TBA					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...				Citation and Details BindingDB Entry DOI: 10.7270/Q2280BR0
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311635 (Ex. Cpd. 87 | US10807986, Example 87 | US11046696,...) Show SMILES COCc1ccc(NC(=O)c2c(C#CC3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C26H29N5O3/c1-26(11-12-26)31-20(8-5-17-9-13-34-14-10-17)21(22-23(27)28-16-29-24(22)31)25(32)30-19-6-3-18(4-7-19)15-33-2/h3-4,6-7,16-17H,9-15H2,1-2H3,(H,30,32)(H2,27,28,29)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...				US Patent US10155768 (2018) BindingDB Entry DOI: 10.7270/Q2X350J3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311691 (Ex. Cpd. 143 | US10807986, Example 143 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3(O)CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C27H31N5O4/c1-26(10-11-26)32-20(4-3-9-27(34)12-14-36-15-13-27)21(22-23(28)29-17-30-24(22)32)25(33)31-19-7-5-18(6-8-19)16-35-2/h5-8,17,34H,9-16H2,1-2H3,(H,31,33)(H2,28,29,30)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret [V804L] (Homo sapiens (Human))	BDBM311673 (Ex. Cpd. 125 | US10807986, Example 125 | US1104669...) Show SMILES COCc1ccc(NC(=O)c2c(C#CCC3(O)COC3)n(c3ncnc(N)c23)C2(C)CC2)cc1 Show InChI InChI=1S/C25H27N5O4/c1-24(10-11-24)30-18(4-3-9-25(32)13-34-14-25)19(20-21(26)27-15-28-22(20)30)23(31)29-17-7-5-16(6-8-17)12-33-2/h5-8,15,32H,9-14H2,1-2H3,(H,29,31)(H2,26,27,28)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.600	n/a	n/a	n/a	n/a	n/a	n/a
Taiho Pharmaceutical Co., Ltd. US Patent					Assay Description Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...				US Patent US10807986 (2020) BindingDB Entry DOI: 10.7270/Q29G5QWG
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 813 total )  |  Next  |  Last  >>

Jump to: